ReviewTherapeutic advances in vaccines2014
Successes and challenges in varicella vaccine.
Review in Therapeutic advances in vaccines, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Varicella-zoster virus seroprevalence among reproductive-age women in Iran: a meta-analysis and implications for targeted immunization.BMC infectious diseases · 2025Pooled it
- Varicella zoster virus infection.Nature reviews. Disease primers · 2026Review
- Duration of immunity following infection with moderately virulent ASFV.PLoS pathogens · 2026Article
- Article
- Validating the Predictions of a Dynamic Transmission Model Using Real-World Data from a Universal Varicella Vaccination Program in Germany.Journal of market access & health policy · 2025Article
- Seroprevalence of Varicella-Zoster Virus and the Need for Herpes Zoster Vaccination Among Adults in Saudi Arabia.Cureus · 2025Article
- The association between healthcare access and shingles vaccination among older adults in Virginia, United States.PloS one · 2025Article
- Expanded spectrum of varicella disease and the need for vaccination in India.Human vaccines & immunotherapeutics · 2024Article
- A Better Understanding of the Clinical and Pathological Changes in Viral Retinitis: Steps to Improve Visual Outcomes.Microorganisms · 2024Review
- Changing age pattern and diverse outcomes of herpes zoster ophthalmicus: exploring the temporal trend, decrease in incident age and influence of treatment strategies.International ophthalmology · 2024Article
- Disseminated vaccine-strain varicella-zoster virus reactivation in an adolescent with secondary immunodeficiency: a case report and literature review.BMC infectious diseases · 2024Review
- Immunity to Varicella Zoster Virus in Healthcare Workers: A Systematic Review and Meta-Analysis (2024).Vaccines · 2024Review
- Study on Varicella-Zoster Virus Antibody Levels among Children Aged 1-7 Years in Changzhou, China.Vaccines · 2024Article
- Effectiveness of two-dose vs. one-dose varicella vaccine in children in Shanghai, China: a prospective cohort study.Frontiers in public health · 2024Article
- Detection of Human Herpesviruses in Sera and Saliva of Asymptomatic HIV-Infected Individuals Using Multiplex RT-PCR DNA Microarray.Pathogens (Basel, Switzerland) · 2023Article
- Global varicella vaccination programs.Clinical and experimental pediatrics · 2022Article
- Worldwide Evolution of Vaccinable and Nonvaccinable Viral Skin Infections: Google Trends Analysis.JMIR dermatology · 2022Article
- Profile and dynamics of infectious diseases: a population-based observational study using multi-source big data.BMC infectious diseases · 2022Observational
- Where are the vesicles? A case report of Ramsay Hunt syndrome.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2022Article
- Induced pluripotent stem cell-based disease modeling and prospective immune therapy for coronavirus disease 2019.Cytotherapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Varicella is a highly contagious disease caused by primary infection with varicella zoster virus (VZV). VZV infection, as well as varicella vaccination, induces VZV-specific antibody and T-cell-mediated immunity, essential for recovery. The immune responses developed contribute to protection following re-exposure to VZV. When cell-mediated immunity declines, as occurs with aging or immunosuppression, reactivation of VZV leads to herpes zoster (HZ). It has been almost 20 years since universal varicella vaccination has been implemented in many areas around the globe and this has resulted in a significant reduction of varicella-associated disease burden. Successes are reviewed here, whilst emphasis is put on the challenges ahead. Most countries that have not implemented routine childhood varicella vaccination have chosen to vaccinate high-risk groups alone. The main reasons for not introducing universal vaccination are discussed, including fear of age shift of peak incidence age and of HZ incidence increase. Possible reasons for not observing the predicted increase in HZ incidence are explored. The advantages and disadvantages of universal vs targeted vaccination as well as different vaccination schedules are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.